ACAD position history
The shares of Acadia Pharmaceuticals (ACAD) that Palo Alto Investors LP reported in each quarter’s 13F.
Shares held by quarter
New Add Reduce Exit
- 2021 Q3: 2,337,877 shares, $39M, 2.3% of portfolio
- 2021 Q4: 2,337,877 shares, $55M, 3.5% of portfolio
- 2022 Q1: 2,251,834 shares, $55M, 4.2% of portfolio, Reduce −3.7%
- 2022 Q2: 1,678,196 shares, $24M, 2.1% of portfolio, Reduce −25.5%
- 2022 Q3: 1,678,196 shares, $27M, 2.2% of portfolio
- 2022 Q4: 2,376,369 shares, $38M, 3.2% of portfolio, Add +41.6%
- 2023 Q1: 2,405,793 shares, $45M, 3.8% of portfolio, Add +1.2%
- 2023 Q2: 2,405,793 shares, $58M, 4.7% of portfolio
- 2023 Q3: 2,405,793 shares, $50M, 4.7% of portfolio
- 2023 Q4: 4,819,112 shares, $151M, 13.6% of portfolio, Add +100.3%
- 2024 Q1: 2,414,943 shares, $45M, 5.0% of portfolio, Reduce −49.9%
- 2024 Q2: 2,418,841 shares, $39M, 4.6% of portfolio, Add +0.2%
- 2024 Q3: 2,523,956 shares, $39M, 5.0% of portfolio, Add +4.3%
- 2024 Q4: 2,748,599 shares, $50M, 7.8% of portfolio, Add +8.9%
- 2025 Q1: 2,663,925 shares, $44M, 8.4% of portfolio, Reduce −3.1%
- 2025 Q2: 2,563,209 shares, $55M, 11.8% of portfolio, Reduce −3.8%
- 2025 Q3: 2,466,684 shares, $53M, 9.7% of portfolio, Reduce −3.8%
- 2025 Q4: 2,484,031 shares, $66M, 9.2% of portfolio, Add +0.7%
- 2026 Q1: 2,872,695 shares, $64M, 9.8% of portfolio, Add +15.6%
- 2026 Q2: 2,864,096 shares, $72M, 10.0% of portfolio, Reduce −0.3%
| Holdings date | Value | % of holdings | Shares | Filing date | All 13F holders |
|---|